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Abstract:  Objective:  This  study  aimed  to  measure  and  correlate  the  expression  of  
insulin-like growth factor receptor-1 (IGF-1R) and the Lewis(y) antigen in ovarian cancer 
cell  lines  and  tissue  samples.  Methods:  Reverse  transcriptase  PCR  (RT-PCR),  Western 
blotting,  immunoprecipitation,  immunohistochemistry,  and  immunofluorescence  
double-labeling techniques were applied to detect and measure the expression of Lewis(y) 
and  IGF-1R.  Results:  In  α1,2-fucosyltransferase  (α1,2-FT)-transfected  cells,  IGF-1R 
expression  was  significantly  upregulated  compared  with  cells  that  do  not  overexpress  
α1,2-FT (P < 0.05). The amount of Lewis(y) expressed on IGF-1R increased 1.81-fold in 
α1,2-FT-overexpressing cells (P < 0.05), but the ratio of Lewis(y) expressed on IGF-1R to 
total IGF-1R was unaltered between two cells (P > 0.05). In malignant epithelial ovarian 
tumors, the positivity rates of Lewis(y) and IGF-1R detection were 88.3% and 93.33%, 
respectively, which is higher than the positivity rates in marginal (60.00% and 63.33%, all 
P  <  0.05),  benign  (33.00%  and  53.33%,  all  P  <  0.01),  and  normal  (0%  and  40%,  all 
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P < 0.01) ovarian samples. No correlations were detected in positivity rates of Lewis(y) or 
IGF-1R expression with respect to clinicopathological parameters in ovarian cancers (all  
P > 0.05). Both IGF-1R and Lewis(y) were highly expressed in ovarian cancer tissues, and 
their expression levels were positively correlated (P < 0.05). Conclusion: Overexpression 
of Lewis(y) results in overexpression of IGF-1R. Both IGF-1R and Lewis(y) are associated 
with the occurrence and development of ovarian cancers.  
Keywords:  epithelial  ovarian  tumor;  Insulin-like  growth  factor  receptor-1;  Lewis(y) 
antigen; immunohistochemistry; immunofluorescence double labeling method 
 
1. Introduction 
Ovarian  cancer has the  highest mortality of all  female  genital tract tumors, and effective early 
diagnostic methods are lacking. Alterations in cell membrane-associated carbohydrate antigens are 
closely linked with malignancy, invasion, and metastasis of cells. Ovarian cancer is characterized by 
changes in type II sugar chains, and more than 75% of epithelial ovarian cancers overexpress the 
Lewis(y) antigen to some extent [1]. Lewis(y) antigen is a difucosylated oligosaccharide containing 
two  fucoses,  and  is  carried  by  glycoconjugates  (glycoproteins  and  glycolipids)  on  the  plasma 
membrane.  Lewis(y)  antigen  is  expressed  predominately  during  embryogenesis.  Under  normal 
physiological  conditions,  its  expression  in  adults  is  restricted  to  the  surface  of  granulocytes  and 
epithelium [2]. However, overexpression of Lewis(y) antigen is frequently found in human cancers 
and has been shown to be associated with poor prognosis [3,4]. 
We previously transfected the ovarian cancer cell line RMG-I with human α1,2-fucosyltransferase 
(α1,2-FT) gene, which catalyzes the fucosylation of Lewis(y), to establish the Lewis(y)-overexpressing 
cell  line,  RMG-I-H.  Compared  to  RMG-I  cells,  which  express  low  amounts  of  Lewis(y)  antigen, 
RMG-I-H  cells exhibit enhanced proliferation,  adhesion, invasion, metastasis, and drug  resistance, 
indicating that Lewis(y) plays a critical role in the progression to and resistance of ovarian cancer [5–7]. 
Insulin-like growth factor receptor-1 (IGF-1R) is a transmembrane glycoprotein consisting of two α, 
β chains. Among the human IGF system reported to date, IGF-1R plays a vital role in fetal growth and 
linear growth of the skeleton and other organs [8]. High level expression of IGF-1R has been implicated 
in several different cancers. Abundant data from cell culture, animal, and human epidemiologic studies 
have suggested that IGF-IR regulate all aspects of the malignant phenotype [9–12] according to its 
extent of glycosylation [13]. 
In the present study, we investigated the expression and the correlation of Lewis(y) and IGF-1R in 
ovarian serous and mucinous carcinoma tissue specimens by using immunohistochemical method. At 
the same time, double-labeling immunoﬂuorescence, co-immunoprecipitation, Western blotting and 
PCR methods were used to further elucidate the correlation of Lewis(y) antigen and IGF-1R. Our 
study provides a theoretical mechanism of ovarian carcinogenesis, development mechanisms, and a 
possible target for the development of biological treatment. 
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2. Results 
2.1. IGF-1R mRNA and Protein Expression in RMG-I and RMG-I-H Cells before and after Antibody 
Blocking 
The  relative  expression  of  IGF-1R  mRNA  (3.49  ±  0.08)  in  RMG-I-H  cells,  as  measured  by  
RT-PCR, was significantly higher than that in RMG-I cells (1.84 ± 0.04) (P < 0.05) [Figure 1(A)]. 
After Lewis(y) antigen on RMG-I-H cells was blocked by 10 µg/ml of monoclonal anti-Lewis(y), the 
expression of IGF-1R mRNA decreased gradually with duration of blocking (P < 0.05), reaching a 
minimum at 24 h of blocking [Figure 1(B)]. Similarly, Western blotting demonstrated that the relative 
expression of IGF-1R protein (1.13 ± 0.07) in RMG-I-H cells was significantly higher than that in 
RMG-I cells (0.66 ± 0.12) (P < 0.05) [Figure 1(C)], and when Lewis(y) was blocked with monoclonal 
antibody,  the  expression  of  IGF-1R  protein  decreased  gradually  with  treatment  time  (P  <  0.05), 
reaching a minimum at 24 h [Figure 1(D)]. 
Figure 1. Analysis of IGF-1R after cells transfected with α1,2-FT gene and the expression 
of IGF-1R of RMG-I-H cell line in control and anti-Lewis(y) monoclonal antibody treated 
groups (A, B, C, D), and expression of IGF-1R proteins and the Lewis(y) content of the 
glycans of IGF-1R before and after α1,2-FT gene transfection (E). A1: RT-PCR profiles of 
IGF-1R in RMG-I and RMG-I-H cell lines. B1: RT-PCR results of mRNA expression of 
IGF-1R of RMG-I-H cell line in control and anti-Lewis(y) monoclonal antibody treated 
groups.  C1:  Western  Blot  profiles  of  IGF-1R  in  RMG-I  and  RMG-I-H  cell  lines. 
D1: Western Blot results of protein expression of IGF-1R of RMG-I-H cell line in control  
and  anti-Lewis(y)  monoclonal  antibody  treated  groups.  E1:  Western  blot  profiles  of 
immunoprecipitated IGF-1R protein using corresponding antibodies and Lewis(y) antibody. 
A2,  B2,  C2,  and  D2:  Relative  amount  of  RT-PCR  or  Western  Blot  profiles. 
E2: Densitometric quantification of IGF-1R   and Lewis(y),   in E1 and calculation of  ① ①
Lewis(y)  expression/IGF-1R    (set  the  ③ RMG-I  cells  as  100%)  (n  =  3).  *  P  <  0.01 
compared to RMG-I. (IP: Immunoprecipitation by the antibody to IGF-1R; WB: Western 
immunoblot with the antibodies to IGF-1Ror Lewis(y)). A-E are the representative of three 
independent and reproducible experiments.   
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Figure 1. Cont. 
 
  
2.2. Expression of IGF-1R Protein and Lewis(y) on the Surface of RMG-I and RMG-I-H Cells and in 
Epithelial Ovarian Cancer Tissues  
The  expression  of  Lewis(y)  on  IGF-1R  was  observed  by  immunoprecipitation  of  IGF-1R  and 
Western  blotting  with  a  monoclonal  antibody  against  Lewis(y).  The  total  amount  of  Lewis(y)  on  
IGF-1R was increased in α1,2-FT-transfected RMG-I-H cells by up to 1.81-fold compared to RMG-I 
cells (P < 0.05). However, the ratio of total Lewis(y) on IGF-1R to total IGF-1R protein was unaltered Int. J. Mol. Sci. 2011, 12  6785 
 
because  total  IGF-1R  was  elevated  to  the  same  magnitude  as  Lewis(y)  (P  >  0.05)  [Figure  1(E)]. 
Immunofluorescence double-labeling of RMG-I-H cell and ovarian cancer tissue detected Lewis(y) 
predominantly localized to the cell membrane (green fluorescence) and IGF-1R localizing mostly to 
the cell membrane but occasionally to the cytoplasm (red fluorescence). Merged images suggested 
colocalization of IGF-1R and Lewis(y) on cytolemma (Figure 2, yellow fluorescence). 
Figure  2.  IGF-1R  and  Lewis(y)  colocalize  in  ovarian  carcinomar  cell  RMG-I-H  and 
ovarian  malignant  tumor;  using  double-labeling  immunofluorescence  method.  
IGF-1R (A1, B1), Lewis(y) (A2, B2), merged image (A3, B3, original magnification × 400). 
 
2.3. Expression of Lewis(y) and IGF-1R in Various Ovarian Tissues 
In malignant epithelial ovarian tumors, Lewis(y) expression was generally increased, with staining 
localizing primarily to the cell membrane and occasionally to the cytoplasm. The positivity rate of 
Lewis(y)  detection  in  these  samples  was  88.33%,  substantially  higher  than  the  positivity  rate  in 
marginal samples (60.00%) (P < 0.05) and in benign tumors (33.33%) (P < 0.01). The difference in 
positivity rates of Lewis(y) between marginal ovarian tumors and benign tumors was not statistically 
significant (P > 0.05).  In normal epithelial ovarian tissues, the Lewis(y) antigen was not detected 
(Table 1).  
Table 1. The expression of Lewis(y) and IGF-1R in different ovarian tissues. 
Groups  Cases 




IGF-1R  Positive 
Cases 
Rate  
(%)  -  +  ++  +++  -  +  ++  +++ 
Malignant 
group 
60  7  15  20  18  53  88.33 *  4  10  23  23  56  93.33 * 
Borderline 
group 
30  12  6  11  1  18  60.00 †  11  9  7  3  19  63.33 ‡ 
Benign 
group 
30  20  6  4  0  10  33.33  14  9  6  1  16  53.33 
Normal 
group 
20  20  0  0  0  0  00.00  12  6  2  0  8  40.00 
* Compared with borderline and benign group, † Compared with the benign group; ‡ Compared with benign 
and normal tissue group. Int. J. Mol. Sci. 2011, 12  6786 
 
The expression of IGF-1R was mainly localized to the cell membrane with sparse localization to the 
cytoplasm and nucleus. In malignant epithelial ovarian tumors, the positive rate of IGF-1R detection 
(93.33%)  was  significantly  higher  than  those  in  marginal  (63.33%)  (P  <  0.05),  benign  (53.33%)  
(P < 0.05), and normal ovarian samples (40%) (P < 0.01). Pairwise comparisons between marginal, 
benign, and normal ovarian samples identified no significant differences in positivity rates (all P > 0.05) 
(Table 1, Figure 3). 
Figure 3. Immunohistochemical staining in ovarian malignant tumor (A1, A2), borderline 
tumor  (B1,  B2),  benign  tumor  (C1,  C2),  and  normal  ovarian  tissue  (D1,  D2).  IGF-1R  
(A1, B1, C1, D1) and Lewis(y) (A2, B2, C2, D2; original magnification × 200). 
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2.4. Relationship between Expression of IGF-1R and Antigen Lewis(y), and Clinical Features of 
Ovarian Cancer  
In ovarian serous cystadenoma tissues, the positivity rate of Lewis(y) detection was 90.00% and did 
not differ significantly from the positivity rate in mucinous cystadenoma (86.67%) (P > 0.05). The 
positivity  rate  of  Lewis(y)  detection  in  stage  III-IV  ovarian  cancer  was  95.24%,  which  was  not 
significantly higher than that in stage I-II (84.62%) (P > 0.05). The positivity rates of Lewis(y) among 
high-, moderate- and low-differentiation groups of ovarian cancer were 80.95%, 85.71%, and 100%, 
respectively,  but  this  increase  in  positivity  rate  with  a  decrease  in  differentiation  level  was  not 
statistically  significant  (P  >  0.05).  The  positivity  rate  of  Lewis(y)  detection  in  the  lymph  node 
metastasis  group  (100%) was not significantly  higher than that in the  lymph node metastasis-free 
group (85.42%) (P > 0.05) (Table 2).  
The positivity rates of IGF-1R detection in serous and mucinous cystadenoma were 90% and 80%, 
respectively, which did not represent a significant difference (P > 0.05). The positivity rates of IGF-1R 
in ovarian cancer stages III-IV and I-II were 85.71% and 84.62%, respectively, which also was not 
significant (P > 0.05). In high-, moderate-, and low-differentiation ovarian cancer tissues, the positivity 
rates of IGF-1R were 76.19%, 85.71%, and 94.44%, respectively, and no statistical significance was 
detected among the three group comparisons (P > 0.05). The positivity rate of IGF-1R in the lymph 
node  metastasis  group  (91.67%)  was  not  significantly  higher  than  that  in  the  lymph  node  
metastasis-free group (93.33%) (P > 0.05) (Table 2). 
2.5. Staining Intensity of Lewis(y) and IGF-1R with Relation to Clinicopathological Parameters of 
Ovarian Cancer 
We detected and analyzed the staining intensity of ovarian cancer sections that were positive for 
Lewis(y)  by  immunohistochemistry.  In  stage  III-IV  ovarian  cancer,  the  mean  optical  density  of 
Lewis(y) was 0.505 ± 0.072, which was significantly higher than the stage I-II value of 0.455 ± 0.065 
(P  <  0.05).  In  low-differentiation  ovarian  cancer  tissue  positive  for  Lewis(y),  the  mean  optical  
density  of  Lewis(y)  was  0.498  ±  0.084,  which  is  significantly  higher  than  the  value  obtained  for  
high-differentiation  tissues,  0.448  ±  0.017  (P  <  0.05).  When  the  Lewis(y)  staining  intensities  of  
low-differentiation  samples  were  compared  with  moderate  samples  or  moderate  samples  were 
compared  with  high-differentiation  samples,  the  difference  was  not  significant  (P  >  0.05).  These 
results do not support that the staining intensity of Lewis(y) is correlated with the histologic type of 
ovarian cancer or with lymph node metastasis (P > 0.05) (Table 2).  
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Table 2. Association between Lewis(y) and IGF-1R expression, expression intensity and pathological features in ovarian cancer. 
Features  Case 










P  MOD  P 
Pathological type 
Mucous  30  26  86.67 
>0.05 
0.463 ± 0.068 
>0.05 
24  80.00 
>0.05 
0.418 ± 0.044 
>0.05 
Serous  30  27  90.00  0.477 ± 0.016  27  90.00  0.437 ± 0.051 
FIGO stage 
I-II  39  33  84.62 
>0.05 
0.455 ± 0.065 
<0.05 
33  84.62 
>0.05 
0.413 ± 0.047 
＜0.05 
III-IV  21  20  95.24  0.505 ± 0.072  18  85.71  0.444 ± 0.051 
Differentiation level 
High  21  17  80.95 
>0.05 






16  76.19 
>0.05 







Middle  21  18  85.71  0.461 ± 0.054  18  85.71  0.413 ± 0.038 
Low  18  18  100  0.498 ± 0.084  17  94.44  0.455 ± 0.049 
Lymphatic metastasis 
No  48  41  85.42 
>0.05 
0.459 ± 0.078 
>0.05 
40  83.33 
>0.05 
0.420 ± 0.054 
>0.05 
Yes  12  12  100 
0.476 ± 0.057 
11  91.67  0.433 ± 0.060 
*  Compared  the  low-  with  high-differentiation  groups; 
†  Compared  the  low-  with  middle-differentiation  groups; 
‡  Compared  the  middle-  with  
high-differentiation groups. 
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The average optical density of IGF-1R in stage III-IV ovarian cancer was 0.444 ± 0.051, which is 
significantly higher than that in stage I-II (0.413 ± 0.047) (P < 0.05). The average optical density of 
IGF-1R  in  low-differentiated  ovarian  cancer  samples  was  0.455  ±  0.049,  which  was  significantly 
higher than the optical densities measured in moderate- (0.413 ± 0.038) (P < 0.05) and high-differentiation 
samples (0.412 ± 0.052) (P < 0.05). The difference in optical density  between the moderate- and  
high-differentiation  groups  was  not  statistically  significant  (P  >  0.05).  As  with  Lewis(y),  the 
expression intensity of IGF-1R was not correlated with the histological type of ovarian cancer or with 
lymph node metastasis (P > 0.05) (Table 2). In most cases, the ovarian cancer tissues that highly 
expressed Lewis(y) antigen concomitantly expressed high levels of IGF-1R; the expression patterns of 
these were linearly correlated (r = 0.721, P < 0.005) (Figure 4). 
Figure 4. The scatterplot of MOD value of Lewis(y) and IGF-1R in ovarian cancer. 
 
3. Discussion  
Cell surface receptors predominantly are populated by glycoproteins, and the sugar chains of which 
form antenna-like branches to receive information [14–16]. Some hallmarks of malignant tumor cells, 
such  as  adhesion,  migration,  and  proliferation,  are  related  to  changes  in  specific  sugar  chains  or 
residues. Fucosyl residue is a terminal structure of glycan which is involved in the formation of sugar 
moieties of certain key growth factors. Fucose also plays an important role in growth mechanisms of 
tumors [7,17]. Lewis(y) antigen is a cancer-associated, difucosylated oligosaccharide that expression 
in epithelial tissues, and during carcinogenisis, Lewis(y) expression was significantly increased in 60% 
to 90% patients with a poor prognosis [18]. Yin et al. found Lewis(y) has a positive expression rate 
(75%) and a strong positive expression rate (56%) in ovarian carcinoma respectively. Among 11 types 
of ovarian cancer cell lines tested, 7 cell lines were found to be Lewis(y) antigen positive [19]. Baldus 
et al. found that the expression level of Lewis(y) was enhanced with adenoma degeneration and higher 
histological grade in 44 cases of colorectal adenocarcinoma and 42 cases of colorectal adenomas [20], 
suggesting that Lewis(y) antigen expression is related to the cell's degree of malignancy. Our previous Int. J. Mol. Sci. 2011, 12  6790 
 
work also demonstrated that increasing Lewis(y) expression leads to increased cell proliferation and 
enhanced adhesion, invasion, metastasis, and drug-resistance [5–7]. In this study, we confirmed our 
results in tissue samples: Lewis(y) was highly expressed in ovarian cancer tissues, and its positivity 
rate reached 88.33%, which was significantly higher than the detection rates of marginal cancer tissues 
(60.00%) (P < 0.05) or benign tumors (33.33%) (P < 0.01). In addition, the expression intensity of 
Lewis(y) increased as the level of malignancy increased (P < 0.05) and in advanced clinical stages of 
ovarian  cancer  (P  <  0.05).  These  results  indicate  positive  correlation  between  the  expression  of 
Lewis(y) antigen and the occurrence and development of ovarian cancer. 
IGF-1R is a membrane receptor which can be activated by insulin-like growth factor (IGF) and 
transmit signals into nucleus via many downstream signaling pathways to further act on target genes 
and involve in regulating the pathogenesis and development of multiple tumors. Numerous studies 
have confirmed that IGF-1R plays an important role in ovarian cancer progression. An et al. report that 
expression of IGF-1R was increased in ovarian cancer compared to benign tumors. IGF-1R was found 
to be higher in tumors with poor prognosis [21]. In this study, IGF-1R expression was consistent with 
the Lewis(y) antigen results. The positivity rate of IGF-1R in ovarian cancer tissues was 93.33%, 
significantly higher than in borderline tumor (63.33%), benign tumor (53.33%) (P < 0.05), and normal 
ovarian  tissue  samples  (40%)  (P  <  0.01).  The  expression  intensity  of  IGF-1R  increased  with  the 
malignancy level (P < 0.05) and was correlated with the operational stage (P < 0.05). Analysis of 
staining intensity in ovarian cancer tissues indicated that Lewis(y) was linearly correlated with IGF-1R 
(r = 0.721, P < 0.005). Furthermore, using the double-labeling immunoﬂuorescence method, we found 
that Lewis(y) and IGF-1R are located in the same position. The evidence suggests that IGF-1R both be 
involved in the mechanisms underlying development of ovarian cancer and conﬁrms the correlation of 
Lewis(y) and IGF-1R.  
Most  epithelial  tumor  cells  overexpress  the  Lewis(y)  antigen,  and  this  may  result  in  
Lewis(y)-induced modification of receptor structures on the cell surface. Basu et al. reported that 
epithelial growth factor receptor (EGFR) in Lewis(y) overexpressing tumor cells exhibit surface-exposed 
Lewis(y) moieties [22]. We detected that Lewis(y) structures were present not only on EGFR but also 
on  CD44  [23,24].  Insulin-like  growth  factor  receptor-1  is  initially  synthesized  as  a  single-chain 
proreceptor polypeptide and is processed by glycosylation, proteolytic cleavage, and covalent bonding 
to assemble into a mature heterotetramer [25]. Despite overexpression and invasion promoting ability 
of  Lewis(y),  and  IGF-1R  being  separately  reported  in  various  types  of  human  cancer,  a  direct 
association between Lewis(y) and IGF-1R has never been described. In this study, we demonstrate that 
IGF-1R mRNA and protein are elevated in RMG-I-H cells, which was substantially increased with 
Lewis(y).  Exposure  to  anti-Lewis(y)  antibodies  could  downregulate  IGF-1R  expression  in  a  time-
dependent manner. Lewis(y) was shown to be present in the oligosaccharides of IGF-1R. Notably, the 
relative content of Lewis(y) structures expressed on IGF-1R was not significantly different between 
RMG-I  and  RMG-I-H  cells.  Our  previous  results  support  that  Lewis(y)  affects  cellular  biological 
behaviors (e.g., cell proliferation, apoptosis inhibition) by influencing the activation of signal transduction 
pathways [26,27]. We speculate that Lewis(y) activated downstream signaling transduction pathways 
and growth signals are delivered to the nucleus, leading to accelerated gene transcription of IGF-1R in 
nucleus, and finally promoting the expression of IGF-1R. Then the amplification of IGF-1R gene and 
overexpression of its protein product closely relate to the poor prognosis in cancer patients. Int. J. Mol. Sci. 2011, 12  6791 
 
In summary, transfection of the ovarian cancer cell line RMG-I with α1,2-FT leads to increased 
Lewis(y) content on surface-expressed IGF-1R proteins, suggesting that the elevated expression level 
of Lewis(y) and IGF-1R are associated with ovarian cancer. Although the specific mechanisms in this 
process still need to be elucidated, our results lend insight to a better understanding of the pathogenesis, 
development, and treatment of ovarian cancer. 
4. Material and Method  
4.1. Reagents and Cells 
The RMG-I cell line, which was originated from human ovarian clear cell carcinoma, donated by 
Professor Iwamori Masao of Tokyo University of Japan. α1,2-FT gene transfected RMG-I cell line was 
established as previously reported [25], named as RMG-I-H. The following reagents were purchased 
from commercial sources: DMEM and fetal bovine serum (FBS) from Hyclone (Logan, UT, USA); 
trypsin  and  ethylenediamine  tetraacetic  acid  (EDTA)  from  Amresco;  Mouse  anti-human  Lewis(y) 
mAb  (clone  A70-  C/C8)  was  purchased  from  Abcam  (England).  Rabbit  polyclonal  anti  IGFR1 
antibody, HRP-labeled second antibodies and protein G plus-agarose were obtained from Santa Cruz 
(USA). Goat monoclonal anti-rabbit immunoglobulin G tetramethy lrhodamine isothiocyanate (TRITC) 
and  goat  monoclonal  anti-mouse  immunoglobulin  G  fluorescein  isothiocyanate  (FITC)  were 
purchased from  Zhongshan Biotechnology (Wuhan, China). The immunohistochemical SP kit was 
purchased  from  Mai  Xin  Company  (Fujian,  China).  Trizol,  primers  and  Reverse  Transcription 
Polymerase Chain Reaction (RT-PCR) reagents came from TaKaRa Company (Dalian, China). 
4.2. Patients and Tissue Samples 
One hundred forty chosen parafﬁn samples are obtained from the operations done from 2000 to 
2009 in the department of gynecology and obstetrics of our hospital. All the tissue sections have a ﬁnal 
diagnosis by specialists. There are 60 cases of primary malignant ovarian tumors (including 30 mucous 
and 30 serous cystadenocarcinomas); 30, borderline ovarian tumor; 30, benign ovarian tumor; and 20, 
normal ovarian tissues (from the normal ovarian tissue excised in the cervical cancer operations). The 
mean age of the sepatients is 47.89 years (15–73 years). The age range of the ovarian cancer group is 
36 to 73 years; median age is 53.5years. The age range of the border line ovarian tumor group is 22 to 
55 years; median age is 35 years. The age ranges of the benign ovarian tumor and normal tissue groups 
are 15 to 72 and 37 to 52 years, respectively; median ages are 44 and 42 years, respectively. Comparing 
these groups, there is no statistical signiﬁcance (P > 0.05). According to the pathological grading, the 
ovarian cancer group contains 21 cases of high differentiation; 21, middle differentiation; and 18, low 
differentiation. The group includes 39 cases of stages I to II and 21 cases of stages III to VI according 
to the International Federation of Gynecology and Obstetrics (FIGO) standard; 12 cases of metastases 
in  the  cavitas  pelvis  nodes.  All  the  cases  are  primary,  and  the  information  is  complete;  chemical 
treatment is not used in all the patients before operations.  
4.3. Cell Culture 
Cells were cultured in DMEM supplemented with 10% FBS at 37 °C, 5% CO2 in humidified air.  Int. J. Mol. Sci. 2011, 12  6792 
 
4.4. Determination of the Expression of IGF-1R mRNAs with Semi-Quantitative RT-PCR  
Total RNA was extracted from the transfected and control cells using Trizol reagent. The cDNA 
was synthesized using Takara RNA PCR Kit and was used as a template for PCR analysis. The primer 
for  IGF-1R  was  F:  5'-CCCATAGCGTGTTCCCTTTA-3',  R:  5'-CTGGGTGACTCTTGCTCTCC-3' 
(fragment  size,  874  bp).  The  primer  forβ-actin  F:  5'-ACAGTCAGCCGCATCTTCTT-3',  
R:  5'-GACAAGCTTCCCGTTCTCAG-3'  (fragment  size,  259  bp).  The  cDNA  was  subjected  to 
denaturation at 95 °C for 5 min, followed by 30 cycles (94 °C, 1 min, 60 °C, 30 s and 72 °C, 30 s) of 
PCR and incubated at 72 °C for 10 min. After amplification, 10 µL of each reaction mixture was 
detected by 2% agarose gel electrophoresis. 
4.5. Analysis of the Proteins of IGF-1R with Western Blotting 
Cells were washed twice with ice-cold PBS, scraped in lysis buffer [50 mM Tris-HCl (pH 7.4),  
150 mM NaCl, 0.5% NP40, 100 mM NaF, 200 µM Na3VO4, and 10 µg/mL each aprotinin, leupeptin, 
PMSF,  and  pepstatin],  and  incubated  for  30  min  at  4  °C  while  rocking.  Lysates  were  cleared  by 
centrifugation (10 min at 12,000 rpm, 4 °C). For immunoblot analysis, 50 µg of total protein were 
resolved by SDS-PAGE and transferred to poly(vinylidene difluoride) membranes. Membranes were 
blocked with TTBS [25 mM Tris-HCl, 150 mM NaCl (pH 7.5), and 0.1% Tween 20] containing 5% 
nonfat milk and incubated overnight at 4 °C with IGF-1R antibody 1:100 in TBST/1% nonfat milk. 
Blots were washed in TTBS and incubated with the appropriate horseradish peroxidaselinked IgG, and 
immunoreactive proteins were visualized with ECL detection system. 
4.6. Analysis of Lewis(y) Expression on IGF-1R Using Immunoprecipitation and Western Blotting 
Washed monolayer cells were lyzed with 200 µL lysis buffer as described above. After protein 
determination, cell lysate containing 500 µg protein was incubated with 5 µg of IGF-1Rantibody, and 
incubated at 4 °C for overnight. Protein G plus-agarose was added and the samples were incubated at 
4 °C for 3 h for immunoprecipitation. 
In  brief,  immunoprecipitated  IGF-1R  were  subjected  to  SDS⁄PAGE,  then  transferred  to  a 
poly(vinylidene difluoride) membrane and treated with 1:1000 diluted anti-Lewis(y) and anti-IGF-1R 
sera in Tris-buffered saline with 5% fat-free dry milk, followed by 1:1000 HRP-labeled secondary 
antibody. Finally, the color was developed with enhanced chemiluminescence reagents, and followed 
by densitometric scanning. 
4.7. Detection of Lewis(y) and IGF-1R Location on Cells and Tumor Tissue by Double-Labeling 
Immunoﬂuorescence  
RMG-I-H is used to cell climbing slice. Tissue sections are chosen tissues that express a strong 
positive  result  in  immunohistochemistry  using  double-labeling  immunoﬂuorescence  method.  The 
sections are incubated primarily with antibodies against Lewis(y) (1:160) and IGF-1R (1:300) at the 
same  time.  Negative  control  sections  are  incubated  with  phosphate  buffered  saline  instead  of  the 
primary antibody. The work concentrations of FITC and TRITC are all 1:100. Nuclei were counterstained 
with DAPI. The empirical procedure is under taken based on kit instruction. Int. J. Mol. Sci. 2011, 12  6793 
 
4.8. Immunohistochemistry 
Histological section of each group of ovarian tissue was 5 µm. The expressions of Lewis(y) and 
IGF-1R  in  ovarian  carcinoma  tissues  are  analyzed  by  immunohistochemical  streptavidi-peroxidase 
staining. A colon cancer sample served as positive control for Lewis(y) antigen, and a breast cancer 
sample was a positive control for IGF-1R. The group with PBS instead of primary antibody was used 
as a negative control. The work concentrations of primary antibodies against Lewis(y) and IGF-1R are 
1:160 and 1:300 respectively. The empirical procedure is under taken based on kit instruction. 
4.9. Assessment Standard and Statistical Analysis 
The presence of brown colored granules on the cell membrane or in the cytoplasm was taken as a 
positive signal, and was divided by color intensity into not colored, light yellow, brown, tan and is 
recorded as 0, 1, 2, and 3, respectively. We choose five high-power fields in series from each slice, 
then score them and take the average percentage of chromatosis cells. A positive cell rate of less than  
5% was a score of 0, a positive cell rate of 5~25% was a score of 1, a positive cell rate of 26~50% was 
a score of 2, positive cell rate of 51~75% was a score of 3, positive cell rate of more than 75% was a 
score of 4. The final score was determined by multiplying positive cell rate and score values: 0~2 was 
equal to negative expression (−), 3~4 was equal to weakly positive (+), 5~8 was equal to moderate 
positive (++), 9~12 was equal to strong positive (+++). The results were read by two independent 
observers to control for variability.  
Microscopic red fluorescence indicated IGF-1R labeled by TRITC, green fluorescence indicated 
Lewis(y) labeled by FITC. Pictures of the two individual fluorescence channels were superimposed 
using  image  analysis  software,  with  a  yellow  fluorescence  indicated  co-localization  of  Lewis(y) 
antigen and IGF-1R.  
The soft ware SPSS version 16.0 (SPSSInc., Chicago, IL, USA) was used for statistical analysis. 
Data expressed as mean ± SD was applied for statistical analysis. The Student’s t test was applied to 
compare data between the two groups, and analysis of variance was applied to compare data among 
multiple groups. The Chi-square (χ
2) test was applied to analyze the expression of Lewis(y) antigen, 
IGF-1R and clinicopathological parameters. The correlation between Lewis(y) and IGF-1R expression 
was tested with the linear regression correlation analysis in ovarian tumor. P < 0.05 was considered 
statistically significant. 
5. Conclusions 
Lewis(y) and IGF-1R are relevant to staging and differentiation of ovarian cancer, suggesting that 
these two molecules mediate a boosting function for the development of ovarian cancers.  
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